Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sequire Conference today: 1. IOP data to be released before end of the quarter and 2. New competitive data (latanoprost + Rhopressa) to be released before end of quarter. With both expected to be positive, expecting a share price bump when announcement is made sometime in the next 70 days.
Give a little pasta towards 0,13
TODAYS TECHNICAL OPINION SKYE 100% BUY!! SHORT ,MEDIUM AND LONGTERM... https://www.barchart.com/stocks/quotes/SKYE/opinion
Cannabis Market can be Brutal in the Summer.. Prices from May to August could get hammered.. But for the Patience investor who has cash at the ready will load big for cheap in many Cannabis stocks including SKYE and rebound in the fall or Santa Rally.... Just letting everyone know don't get discouraged take advantage... As far as SKYE goes its has been under alot of company ticker symbols and usually holds up well... I've been trading for quite few years and I've been through some nasty Summers just a heads up...
Head of Regulatory Affairs and Quality Assurance position just listed:
https://www.linkedin.com/jobs/view/2484364403
Indicators have SKYE As a Strong Buy... https://www.barchart.com/stocks/quotes/SKYE/opinion
April 8, 2021 01:09 PM ET (BZ Newswire) -- Cannabis
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
From the first research of tetrahydrocannabinol(THC) in 1964 by Raphael Mechoulam to the recent findings of the hundreds of cannabinoids that can alleviate symptoms of a plethora of illnesses and diseases, we now know cannabis is more than just weed and about getting high.
Skye Bioscience Inc. (OTCQB:SKYE), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet needs recently presented at the Benzinga Cannabis Capital Conference its approach to treating Glaucoma through unlocking the pharmaceutical value of THC.
Here’s what you need to know.
Glaucoma — An Important Unmet Need
According to a report on vision by the World Health Organization (WHO), at least 2.2 billion people suffer from vision impairment or blindness, of which over 1 billion cases could have been prevented or have yet to be addressed.
Glaucoma is a disease that leads to the progressive damage of retinal ganglion cells, which make up the optic nerve, and without intervention will gradually lead to irreversible blindness. In most cases, there is no pain and the loss of vision occurs gradually from peripheral to central and unfortunately, in many instances, people with glaucoma do not even realize it until they start experiencing some degree of permanent loss of vision
In fact, over 3 million Americans have glaucoma but only half of those know they have it. In addition, this disease accounts for over 10 million visits to physicians per year in the United States, and the estimation of suspected cases are close to 60 million worldwide.
of irreversible blindness and it ranks among the main reasons for the usage of medical marijuana.
A Light In The Horizon — Relevance Of THC To Glaucoma
The primary aim for currently used therapies is to lower intraocular pressure (IOP) to slow the progression. Yet, many patients are unresponsive or develop tolerance to medication leaving notable unmet needs, resulting in more than 50% of patients requiring 2 or more drugs which can increase side effects and reduce compliance. The market has lacked significant innovation, thus presenting an opportunity and need for new classes of therapy.
Cannabinoids have a great impact on the endocannabinoid system (ECS) — eyes are rich with cannabinoid receptors, specifically in tissues involved in managing fluid production and drainage as well as cells responsible for vision.
Multiple independent studies have demonstrated THC’s ability to lower IOP. In fact, the first report that smoking cannabis lowers IOP appeared in the early 1970s, and since then multiple human studies have validated THC’s ability to lower IOP. However there have been challenges creating a viable therapeutic with systemic delivery of THC for glaucoma because of poor,unpredictable pharmacokinetics and potential side effects.
Unlocking the therapeutic value of THC
Skye’s approach is designed to provide advantages over currently approved drugs and natural cannabinoids to treat glaucoma. Skye’s synthetic THC prodrug called THCVHS is engineered to enhance its local delivery — avoiding systemic side effects and enhancing bioavailability in the eye.
In an animal study comparing latanoprost, the glaucoma standard-of-care, THCVHS was superior in a key outcome of lowering IOP. THCVHS may also provide unique neuroprotection to prevent another key cause of vision loss — optical nerve cell death.
Skye is working toward its Phase 1 study planned for H2 2021, which will primarily assess safety and tolerability but will also measure IOP in both healthy subjects as well as a smaller subset of patients with elevated IOP. The nature of glaucoma allows this study to be relatively short and low cost.
Corporate highlights
Skye Bioscience, previously Emerald Biosciences, introduced a series of incoming results from pre-clinical and clinical-enabling studies. Should the results prove positive, they would pave the way for an Investigational New Drug (IND) application into what is a potentially $10 billion drug market.
Some of the company’s highlights include:
Demonstrated greater IOP lowering than market-leading glaucoma therapeutics
Potential neuroprotection capabilities would be a game-changer
Key preclinical data (IOP/neuroprotection) in Q221
First clinical trial: fast; low-cost; will include assessment of intraocular pressure
Many glaucoma licensing deals have been completed in phase 2 or earlier
$40 million market cap
$350 million outstanding common shares
$472.7 million fully diluted shares
Copyright © 2021 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
Ready for the launch?
hey thank you. I still own GWPRF
and I also own CARA
just waiting on this one now
those other 2 are unicorns
Good to see you here.. I Remember you from #GWPRF and #GWPH... You were spot on..
this will RUN as soon as news hits. Been in this stock since the Nemus days.
It still is very unknown and undervalued
I am patient and my shares are free after trading my position
LONG SKYE
Schumer says bill to legalize marijuana Federally will be filed shortly... https://www.marijuanamoment.net/schumer-says-bill-to-legalize-marijuana-federally-will-be-filed-shortly/
WAKE UP OVER HERE... QUIT NAPPING ON THE JOB BOB...
Many people are aware that almost the entire OTC Market has been crashing in unison for the past month or so. Now we may finally know why. On February 18 and February 22, the Market Maker (MM) JANE appeared on 36 of the highest volume stocks in the OTC. Some examples include OZSC, AITX, GAXY, TSNPD, AABB, ENZC, INKW, OPTI, NSAV, PVDG and WDLF. Later that number increased to 78 stocks. February 22 is also the same day that GME and AMC began trending upward again after a dip that lasted for a couple weeks.
Have you ever noticed that many of your big OTC stocks tend to follow the exact same price curves, dips, spikes and dumps at the same time? This manipulation from JANE is why, and based on the timeline of JANE's appearance in these high volume OTC stocks, the evidence suggests that JANE is heavily manipulating the OTC downward using tactics of naked shorting, dark pool selling and Not-Held Orders in some connection with the fight against retail in GME and AMC.
Please check for yourself by going to https://www.otcmarkets.com/otc-link/broker-dealer-directory/JANE and selecting "Common Stock" from the "Type" drop down menu to view the list of stocks that JANE is in. View the historical charts for many of these stocks and watch them follow the same patterns downward beginning February 22nd.”
www.otcmarkets.com
otcmarkets.com
Everybody sleeping?
#SKYE , I FEEL THE NEED FOR SPEED ... LISTEN TO HER HOWL AND ROLL.. CHURNING...
ITS TIME TURN & BURN.. #SKYE RIDE ITS MIGHTY WINGS..GREAT BALLS OF FIRE!!!!!
I need a few more to get to 100K,
This means we all going to add tomorrow.
I know.. I posted it 0.12 is the loading zone if people's got a brain in their head they better be buying... I'm waiting on funds and I will be adding..
8 months ago it was $1, Past three months thre was nothing. NOW its is
The 1 analysts offering 12-month price forecasts for Skye Bioscience Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +1,500.00% increase from the last price of 0.13.
I thinks nobody knows, this is the point where you buy all the shares you can, GMHO
0.12 support holding like Concrete floor going in... Accumulate is the word of the day.. Because that's what's happening here...
No.. It's trading normally and we might see a pop in April and Skye will continue to trade sideways.. But when you'll see the big move will be the fall of this year... If you look at the 5 year chart you'll see the spikes... Plus many stocks have been beat down including this one I've never seen it trade at 0.03 cents in 6 years the Pandemic really hit the market Hard crushed a lot stocks Creating huge buying opportunity.. I'm lucky I got this at 5 cents loaded up... I've seen SKYE when if you got shares at 14 cents it was a steal because you couldn't get this below 20 cents... I'm telling you since 2014.. I've never seen this stock trade below 12 cents ever... Until the Coronavirus Pandemic 2020.. It seems to be bullish and in recovery mode it may take time...
Could it be competion is keeping this, low? This should be way above this share price.
I would say not many.. Brokers will often tell investors that only stocks above $5 can be sold short. Although this may be true for your particular brokerage firm, it is not a requirement set by the Financial Industry Regulatory Authority (FINRA) or the Securities and Exchange Commission (SEC).. For the few financial institutions that will allow shorting of these stocks below a dollar I'd say there's not many here.. https://www.investopedia.com/ask/answers/03/110703.asp
So how many shorts need to cover before friday on this stock??? Any thoughts?
BEEP BEEP 0.1210 LOADING ZONE!!!!!
Citron once shorted all of Emerald companies w/o much care as to which or why and that really depressed this thing when it had quite a nice run prior. Now that it's on its own this company has value little to no debt or overhang so sky is limit. When is this phase 1 data and Australia development happening. All other stocks in industry are taking part in rally we're still on sidelines.
0.12 is just like when we were trading at 0.03 forever... Then Boom.. Will trade sideways here until news or the company has major positive or the Government has some huge policy change.. When this does truly Break out.. I've seen this play run to 0.50 quick fast and in hurry..
Forecasts has this doubling in value in 6-12 months. I hope this goes up slowly, builds value behind it and stays in a bullish channel. Profit-takers, will always take profits and lawsuits are one reason why. However, this is on my radar and many lists as a sound investment, so I'm in!
Watch for steady climb not, a breakout, this is what we want.
Cheerz
Hey I'm holding... As many years as I been trading this stock this is the 1st time I've ever seen a Litigation ever...
I'm locked and loaded.. Just didn't like seeing that BS litigation breach of fiduciary duty according to the law firm..
This is what the Law firm is Alleging breach of fiduciary duty... https://www.investopedia.com/ask/answers/042915/what-are-some-examples-fiduciary-duty.asp
Give me three hours
Ok I will add again. 100k and above
SKYE is extremely BULLISH on all my lists. Let's see where this goes!
I mean it seems kind of silly... They're saying they believe one of the board members was neglecting their duties.... Their timing is impeccable... Would you agree maybe given some a little more time to accumulate...
Just getting started on there Suspicions...
OR is it a game, before we go UP????
So where are we now, is this OK or not ?
I've been invested with quite a few stocks that have litigation I just don't like it , it's a eye sore... Stocks usually still did well I made money but it was unwanted B.S.
If somebody has a complaint, doesnt mean its true, But I agree, some explaining would we nice
Cant say I'm happy about this.. Out of Nowhere.. https://finance.yahoo.com/news/investigation-alert-fields-kupka-shukurov-131000506.html
Become a mod and access to the ibox and stickies are at hand
Maybe someone that is invested here, should get that IBOX filled in with info. This is now on my watchlist. If I tell my group it has be a professional/verified presentation. If you want the steady volume and price appreciation, you should put info in Ibox and Stickies!
Share structure
Filings links
Company info should do it..
Target is actually .30 in 3 months.
I would like to make that happen, but I cannot move the group participants over here, unless the Ibox has info and the Sticky posts have quick info and company growth filing.
Use their 8-K's 10K's
I've been in tickers that had these legs and we've pushed them all the way up to .60/.90 etc.. From Copper.
The OTC is HOT right now!
Cheerz
https://www.sec.gov/edgar/browse/?CIK=1516551&owner=exclude
Yea this is good play.. I've been watching and trading it for years... This has popped to above 0.50 and dollar multiple times.. The Patience will be rewarded here..
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |